What SELECT changed about how semaglutide is discussed, and what it did not posts 31–60

Appreciated. The plain phrasing does more work here than a longer post would.

Coming back to post #44, because the follow-up matters more than the original answer.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

I checked the source rather than the summary, and they differ.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

On SELECT I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.

On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.

I had written a reply contradicting post #48 and deleted it. Here is what survived.

Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.

Old habit: I write down the expected answer before I calculate it.

The confident answers on SELECT and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.

The arithmetic in post #51 is right; the assumption feeding it is the part to check.

Adding the boring version of SELECT, because the interesting version keeps getting posted and the boring one is usually right.

Check the ordinary explanations, in order, and stop when one of them accounts for what you are seeing. Most of the time the second one does.

Second this, and I would have said it less carefully.

Cardiovascular data in people without diabetes is the specific contribution of SELECT, and it is worth being precise that the enrolled population had established cardiovascular disease. That is not the same as the general population and the result should not be quoted as though it were.

Take it as a starting point and not as a specification.

Everything in post #51 holds. The case it does not cover is the one I have.

I keep a log for SELECT specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.

Narrowing post #55, because the general version has more than one answer.

Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.

I would want the raw data before agreeing with my own summary of it.

Solutions of semaglutide can look faintly opalescent without anything being wrong. Visible particulate, fibres or frank cloudiness are a different observation entirely and are worth raising with the supplier rather than reasoning about.

Practical note on SELECT: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.

I read post #55 twice before replying, because I had assumed the opposite.

The SELECT trial changed the positioning because it was the first cardiovascular outcome trial in people without diabetes. That decoupled the cardiovascular argument from glycaemic control, which is why it mattered beyond its own numbers.

Noting that I have skin in this question and have tried to discount for it.

On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.